Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Theravance Bio Ord (TBPH)

Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 921,217
  • Shares Outstanding, K 50,672
  • Annual Sales, $ 64,380 K
  • Annual Income, $ -56,420 K
  • EBIT $ -33 M
  • EBITDA $ -34 M
  • 60-Month Beta 0.14
  • Price/Sales 14.10
  • Price/Cash Flow N/A
  • Price/Book 3.88

Options Overview Details

View History
  • Implied Volatility 118.80% (+1.17%)
  • Historical Volatility 71.86%
  • IV Percentile 73%
  • IV Rank 44.58%
  • IV High 226.65% on 10/17/25
  • IV Low 32.03% on 09/03/25
  • Expected Move (DTE 28) 0.29 (1.54%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 38
  • Volume Avg (30-Day) 24
  • Put/Call OI Ratio 1.03
  • Today's Open Interest 4,130
  • Open Int (30-Day) 4,078
  • Expected Range 18.50 to 19.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.35
  • Number of Estimates 3
  • High Estimate 0.87
  • Low Estimate -0.10
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +212.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.25 +8.93%
on 12/17/25
20.33 -7.58%
on 11/28/25
+1.06 (+5.98%)
since 11/19/25
3-Month
13.50 +39.19%
on 10/15/25
20.33 -7.58%
on 11/28/25
+4.91 (+35.37%)
since 09/19/25
52-Week
7.90 +137.85%
on 04/07/25
20.33 -7.58%
on 11/28/25
+9.06 (+93.11%)
since 12/19/24

Most Recent Stories

More News
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at...

TBPH : 18.79 (+3.36%)
Theravance Biopharma to Participate in Upcoming Investor Conferences

DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025:

TBPH : 18.79 (+3.36%)
Theravance Bio: Q3 Earnings Snapshot

Theravance Bio: Q3 Earnings Snapshot

TBPH : 18.79 (+3.36%)
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DUBLIN , Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of...

TBPH : 18.79 (+3.36%)
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

DUBLIN , Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will be participating at the 36 th International Symposium on the Autonomic Nervous System,...

TBPH : 18.79 (+3.36%)
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

DUBLIN , Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday,...

TBPH : 18.79 (+3.36%)
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen...

TBPH : 18.79 (+3.36%)
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

DUBLIN , Oct. 14, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced that it will be presenting two rapid-fire presentations...

TBPH : 18.79 (+3.36%)
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

DUBLIN , Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference...

TBPH : 18.79 (+3.36%)
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

DUBLIN , Aug. 25, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced completion of enrollment in the open-label...

TBPH : 18.79 (+3.36%)

Business Summary

Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.'...

See More

Key Turning Points

3rd Resistance Point 19.83
2nd Resistance Point 19.32
1st Resistance Point 19.05
Last Price 18.79
1st Support Level 18.27
2nd Support Level 17.76
3rd Support Level 17.49

See More

52-Week High 20.33
Last Price 18.79
Fibonacci 61.8% 15.58
Fibonacci 50% 14.11
Fibonacci 38.2% 12.65
52-Week Low 7.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar